The purpose of this study is to evaluate the safety and tolerability of long-term administration of etanercept in adults with psoriasis who have participated in previous etanercept psoriasis studies. This study will also evaluate the maintenance of the efficacy of etanercept in adults with psoriasis who have participated in previous etanercept psoriasis studies. All subjects enrolled in this study will receive 50 mg once weekly or twice weekly (if qualified after week 12) by subcutaneous injections for at least 48 weeks and up to 72 weeks.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
912
Enbrel 50 mg once weekly or 50 mg twice weekly
Subject incidence of adverse events, including infectious episodes
Time frame: 72 weeks
Changes from baseline in laboratory values
Time frame: 72 weeks
Improvement in Psoriasis Area and Severity Index (PASI) Score in this study relative to baseline in the original study
Time frame: 72 weeks
Proportion of subjects who achieve 0 or 1 (clear or almost clear) in the Physician Global Assessment of psoriasis
Time frame: 72 weeks
Patient Global Assessment of psoriasis
Time frame: 72 weeks
Percent improvement from baseline in the Dermatology Life Quality Index (DLQI) scores
Time frame: 72 weeks
Changes from baseline in SF-36 Health Survey scores
Time frame: 72 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.